Table 3.
Most common side effects of postexposure prophylaxis regimens over the past 10 years.
| Adverse effect |
||||||||
|---|---|---|---|---|---|---|---|---|
| Nausea/ vomiting |
Diarrhea | Headache | Fatigue/ weakness |
Abdominal pain/bloating |
Rash | Neuropsychiatric | Hyperbilirubinemia | |
| ZDV/3TC + LPV/RTV [30] | 66% | 67% | NR | 47% | NR | 11% | NR | NR |
| ZDV/3TC + FPV/RTV [31] | 73% | 58% | NR | 62% | NR | 12% | NR | NR |
| ZDV/3TC + LPV/RTV [ 33] | 48% | 22% | NR | 17% | (Included in nausea/ vomiting total) |
1% | 11% | NR |
| ZDV/3TC + unboosted ATZ [33] |
34% | 7% | 23% | 0% | 16% | |||
| TDF/3TC [34] | 18.8% | 31.3% | 18.8% | 28.1% | 20.3% | NR | NR | NR |
| TDF/FTC [34] | 22.5% | 47.5% | 22.5% | 30.0% | 47.5% | NR | NR | |
| TDF/FTC + LPV/RTV [35] | 59% | 78% | 38% | 78% | NR | 2% | NR | NR |
| ZDV/3TC/TDF [36] | 89% | 40% | NR | 78% | NR | NR | NR | NR |
| TDF/3TC + ATZ/RTV [36] | 64% | 38% | 77% | 87% | ||||
| TDF/FTC + RAL [37] | 27% | 21% | 15% | 14% | 16% | NR | NR | NR |
3TC, lamivudine; ATZ, atazanavir; FPV, fosamprenavir; FTC, emtricitabine; LPV, lopinavir; NFV, nelfinavir; NR, not reported; PI, protease inhibitor; RAL, raltegravir; RTV, ritonavir; TDF, tenofovir; ZDV, zidovudine.